



Resolution n°10-2023-e

No-cost extension for COVID-19 Output in the project entitled “Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs”

Recalling Unitaid Executive Board Resolution R8-2019-e, in which the Board approved the commitment of up to USD 14,457,862 for the project entitled “*Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs*”, implemented by FIND (the Project);

Noting that in accordance with and under the ACT-A authorizations granted by the Executive Board, the Executive Director committed up to an additional US\$ 525,000 to the Project in January 2022, to support the addition of a COVID-19 Output entitled “Developing and deploying advocacy strategies to promote Covid-19 diagnostic testing and linkages to care and treatment in low- and middle-income countries” (the Output);

Noting that FIND has since requested a 12-month no-cost extension of that Output, to complete the originally planned activities and support transition of implemented interventions;

Acknowledging the recommendations of the Secretariat, the Executive Board authorises the Executive Director to extend the Output by a further 12 months commencing from 1 January 2023.

The authorisation is conditional upon signature of formal amendment to the legal agreement for the Project.

Lead Organization: FIND

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 20 June 2023